Investors & Media
Aceragen is a clinical-stage biopharmaceutical company committed to transforming the care of people living with rare pulmonary and rheumatic diseases. Our portfolio includes late-stage programs that we are developing to be innovative therapeutics capable of addressing the unmet medical needs of those individuals.
Feb 06, 2023
Aceragen Announces Recommendation of Data Monitoring Committee in Terra Study Read More
Jan 17, 2023
Idera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic Outlook Read More
Nov 14, 2022
Idera Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update Read More